Argitalpenak (9) Roberto Andrés Escala Cornejo argitalpenak

2023

  1. Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2

    Reumatologia clinica, Vol. 19, Núm. 2, pp. 121

2022

  1. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  2. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab

    Reumatologia Clinica, Vol. 17, Núm. 10, pp. 559-561

  2. Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors

    CASE REPORTS IN ONCOLOGICAL MEDICINE, Vol. 2021

2020

  1. Management of Febrile Neutropenia Associated with SARS-CoV-2 Infection in a Patient with Cancer

    JCO Oncology Practice

  2. Reply to A. Lasagna et al

    JCO Oncology Practice

2018

  1. Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate

    Annals of Nuclear Medicine, Vol. 32, Núm. 8, pp. 568-572

  2. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors

    Urology, Vol. 117, pp. 41-43